Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
ScripsAmerica, Inc. (SCRCQ)
Clifton, NJ, US
ScripsAmerica, Inc. specializes in crafting and selling non-sterile creams for topical and transdermal pain management. Beyond its product offerings, the company provides medication dispensing support to individual doctors and supplies administrative and billing solutions for independent pharmacies. It also functions as a distributor, supplying pharmaceutical goods to standalone drugstores and other healthcare providers. Established in 2008, ScripsAmerica is based in Clifton, New Jersey. The company initially filed for Chapter 11 bankruptcy protection on September 7, 2016, before its reorganization case was subsequently changed to Chapter 7 liquidation on February 8, 2017.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -96.67% | -99.60% | -99.96% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+5,447.5% ★ Q1'15: +1,043.4% (vs Q1'14)
-
EPS growth Medical - Pharmaceuticals: +20.2%+76.8% ★ Q1'15: -7.1% (vs Q1'14)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-6.7% Q1'15: -5.8% (vs Q1'14)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-14.4% Q1'15: -16.9% (vs Q1'14)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q1'15: +207.2% (vs Q1'14)
-
Share dilution Medical - Pharmaceuticals: +0.0%+87.0% Q1'15: +28.1% (vs Q1'14)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.30× Q1'15: -0.29× (vs Q1'14)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Robert Schneiderman | 20.16M | 38.40% | 200.0K | 200.0K | 200.0K | — | IN | United States of America | 2012-02-03 | ↗ |
| 2 | Steve Urbanski | 19.96M | 38.40% | — | — | — | — | IN | United States of America | 2011-11-16 | ↗ |
| 3 | Andrius Pranskevicius | 6.09M | 10.50% | 5.98M | 5.98M | 5.98M | — | IN | Lithuania | 2011-11-30 | ↗ |
| 4 | Ironridge Global IV, Ltd. | 5.65M | 6.80% | — | — | 5.65M | — | OO | British Virgin Islands | 2013-11-12 | ↗ |
| 5 | Jeffrey Andrews | 5.08M | 9.80% | — | — | — | — | IN | United States of America | 2011-11-16 | ↗ |
| 6 | Brendan T. O’Neil | — | 0.00% | — | — | — | — | IN | British Virgin Islands | 2013-11-12 | ↗ |
| 7 | Ironridge Global Partners, LLC | — | 0.00% | — | — | — | — | HC | British Virgin Islands | 2013-11-12 | ↗ |
| 8 | John C. Kirkland | — | 0.00% | — | — | — | — | IN | British Virgin Islands | 2013-11-12 | ↗ |
| 9 | Keith Coulston | — | 0.00% | — | — | — | — | IN | British Virgin Islands | 2013-11-12 | ↗ |
| 10 | Richard H. Kreger | — | 0.00% | — | — | — | — | IN | British Virgin Islands | 2013-11-12 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian Ettinger | Chairman & Chief Executive Officer | 6.0K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SCRCQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
